In working towards the ultimate goal of making therapies available to all patients in need, Fondazione Telethon pursues cooperative strategies to combine its resources and capabilities with those of investors and industrial partners in order to achieve full therapeutic development of its research results.
The final goal: to make our results available to all patients
- Research Projects: access to third parties’ tools and technologies, structuring of collaborations working closely with the Research Office.
- Intellectual Property: protection of research results and management of intellectual property rights.
- Marketing: increase Fondazione Telethon’s visibility among for-profit players in the field (including pharma and biotech companies as well as venture capital firms) and active advertising of the most advanced projects.
- Partnerships and start-up creation: negotiation of agreements with for-profit players in the field.
Ongoing international collaborations
- Orchard Therapeutics: researchers at SR-Tiget are developing gene therapies for some rare genetic diseases (Orchard Therapeutics took the partnership over from Glaxo SmithKline).
- Sofinnova Telethon Fund: a technology transfer fund dedicated to early stage Biotech investments in the rare disease space in Italy.
- European Joint Program on Rare Diseases: the Business Development Office co-leads Research Translation Support.
Companies based on Telethon research
- Epsilen Bio is a company based on a technological platform developed by a SR-Tiget investigators with the goal of developing advanced therapies. Epsilen Bio collaborates with SR-Tiget and received funding from the Sofinnova-Telethon fund.
- Genespire is a company based on the results of SR-Tiget research aimed at developing advances therapies for genetic diseases. Genespire collaborates with SR-Tiget and received funding from the Sofinnova-Telethon fund and from the Sofinnova Capital IX fund.
- AAVantgardeBio is a company based on the results of Tigem research aimed at developing gene therapies for hereditary diseases of the retina. AAVantgarde Bio's technology is based on the existence of platforms based on AAV, or adeno-associated viruses, which are the main viral vector technology used in the application of in vivo gene therapies. Already existing AAV-based platforms have limited gene transport capacity and AAVantgarde Bio responds to this challenge by allowing the transfer of large genes to tissues and cells in vivo. AAvantgarde Bio received funding from the Sofinnova-Telethon fund.
- Innovavector is a company built on TIGEM competences in gene therapy with the aim of designing and testing new techniques for the production, purification and quality control of adeno-associated viral vectors (AAV) for gene therapy use. The company is the product derives from the encounter between Fondazione Telethon and Equiter, a venture capital investor and advisor to the Research and Innovation Fund (RIF).
- Next generation Diagnostic is a company based on TIGEM competences, aimed at developing and testing new diagnostic techniques. The company derives from the encounter between Fondazione Telethon and Equiter, a venture capital investor and advisor to the Research and Innovation Fund (RIF).
COMPOUNDS INDUCING DEGRADATION OF THE CELLULAR PRION PROTEIN
COMPOUNDS REGULATING CELLULAR PRION PROTEIN ACTIVITY